| Literature DB >> 36105935 |
Jie Xu1, Xin Yu2, Zhimin Wang2.
Abstract
Hypertensive disorders of pregnancy are a group of pregnancy-related diseases characterized by the coexistence of pregnancy and elevated blood pressure, which seriously endanger the health of mothers and infants, and are one of the main causes of maternal and perinatal deaths. The purpose of this paper is to investigate the clinical analysis of vitamin E and astragalus in the adjuvant treatment of hypertensive disorders in pregnancy and to describe the learning model. This paper puts forward the problem of clinical treatment, which is established on the basis of adjuvant therapy, then narrates around the clinical characteristics of gestational hypertension, and designs and analyzes the experimental design and analysis of adjuvant therapy with vitamin E and astragalus. The experimental results showed that the delivery methods of the three groups of patients were compared P < 0.05. Compared with the traditional Chinese medicine control group and the vitamin E control group, there were more vaginal births in the experimental group, 36 patients in total. It shows that astragalus and vitamin E can alleviate the disease in different aspects and can effectively intervene in gestational hypertension.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36105935 PMCID: PMC9467709 DOI: 10.1155/2022/8480106
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1Linear classifier.
Figure 2Separating hyperplane.
Figure 3Support vector machine.
Figure 4Viterbi algorithm.
Figure 5Astragalus.
Figure 6Vitamin E.
Age distribution of the three groups ().
| Evaluation indicators | Test group | Astragalus control group | Vitamin E control group |
|
|
|---|---|---|---|---|---|
| Age | 0.29 | 0.75▲ | |||
| Mean + SD | 31.05 ± 4.59 | 30.20 ± 3.20 | 30.90 ± 2.75 | ||
| Min–max | 22~38 | 23~35 | 24~36 | ||
| 95% CI ( | 23.81~33.16 | 28.61~31.64 | 29.33~32.33 | ||
|
| 40 | 40 | 40 |
Note: one-way analysis of variance was used; ▲: compared with the age of the three groups, P > 0.05.
The distribution of gestational age in the three groups ().
| Evaluation indicators | Test group | Astragalus control group | Vitamin E control group |
|
|
|---|---|---|---|---|---|
| Gestational week (week) | 2.19 | 0.12▲ | |||
| Mean + SD | 29.40 ± 1.80 | 29.10 ± 2.13 | 30.75 ± 3.31 | ||
| Min–max | 26~31 | 25~32 | 24~30 | ||
| 95% CI ( | 28.64~30.21 | 28.18~30.13 | 27.40~29.18 | ||
|
| 40 | 40 | 40 |
Note: one-way analysis of variance was used; ▲: comparison of gestational weeks among the three groups, P > 0.05.
Parity distribution of the three groups.
| Evaluation indicators | Test group | Astragalus control group | Vitamin E control group |
|
|
|---|---|---|---|---|---|
| Parity (example) | 0.53 | 0.77▲ | |||
| Primipara | 28 | 30 | 32 | ||
| Multiparous | 12 | 10 | 8 | ||
|
| 40 | 40 | 40 |
Note: nonparametric test was used for analysis; ▲: comparison of the educational level of the three groups of patients, P > 0.05.
Distribution of the three groups of diseases.
| Evaluation indicators | Test group | Astragalus control group | Vitamin E control group |
|
|
|---|---|---|---|---|---|
| Disease composition ratio (cases) | 0.44 | 0.80▲ | |||
| Gestational hypertension | 16 | 14 | 12 | ||
| Mild preeclampsia | 24 | 26 | 28 | ||
|
| 40 | 40 | 40 |
Note: row x list chi-squared test was used for analysis; ▲: comparison of disease constituent ratios among the three groups of patients, P > 0.05.
Figure 7Results of the efficacy of TCM syndromes in the three groups.
Figure 8Distribution of delivery and neonatal perinatal outcomes among the three groups of pregnant women.
Figure 9Comparison of mean pulsatile pressure and 24 h urine protein data before and after treatment in the three groups.